You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. CYTOKINETICS INC

Cytokinetics Inc XNAS: CYTK

Cytokinetics Inc Live Share Price Today, Share Analysis and Chart

Download real time

39.48 0.00 (0.00%)

42.58% Fall from 52W High

3,036 XNAS Volume

XNAS 21 Apr, 2025 9:29 AM (EDT)

Watchlist

Portfolio

Share

Cytokinetics Inc Key Metrics

Default

Market Capitalization

High in industry
4,705.5

PE TTM

Negative PE TTM
-8

PEG TTM

High in industry
0.7

Price to Book

Negative Price to Book
-34.8

Institutional holding current Qtr %

High in industry
113.3

Revenue Growth Qtr YoY %

High in industry
912.4

Operating Revenue growth TTM %

High in industry
145.3

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-9.6

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-12

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-821.4

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-2,902.7

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-14.2

RoA Annual %

Negative RoA Annual %
-53
All financials are in USD Million and price data in USD
VIEW MORE

8

S

9

W

3

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Cytokinetics Inc Live Price Chart

Switch to TradingView
Created with Highcharts 9.0.1Chart context menu13. May10. Jun8. Jul5. Aug2. Sep30. Sep28. Oct25. Nov23. Dec20. Jan17. Feb17. Mar14. Apr200820102012201420162018202020222024304050607080020MZoom1D1W1M3M1Y5YAllApr 21, 2024→Apr 21, 2025trendlyne.com

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260250500Actual RevenueAvg. Estimate
Miss

Cytokinetics Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-5.3
Avg. Estimate
-5.7
Low Estimate
-6.7
High Estimate
-4.9
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 8.9% in FY25

Consensus Recommendation

21 ANALYST Recommendations
BUY

Created with Highcharts 7.2.23Hold8Buy10Strong Buy

The consensus recommendation from 21 analysts for Cytokinetics Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Cytokinetics Inc Stock Analysis

Cytokinetics Inc stock analysis with key metrics, changes, and trends.

Cytokinetics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$18.47 M145.34%positive

Annual Revenue rose 145.34%, in the last year to $18.47 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

Annual Net Profit$589.53 M12.03%negative

Annual Net Profit fell 12.03% in the last year to $589.53 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio-7.98-negative

Price to Earning Ratio is -7.98, which is negative.

Stock Price$39.48-41.55%negative

Stock Price fell 41.55% and underperformed its sector by 49.43% in the past year.

Quarterly Revenue$16.93 M912.38%positive

Quarterly Revenue rose 912.38% YoY to $16.93 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

Quarterly Net profit$150.02 M9.59%negative

Quarterly Net profit fell 9.59% YoY to $150.02 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Mutual Fund Holding87.39 %0.01%positive

Mutual Fund Holding increased by 0.01% in the last quarter to 87.39.

Promoter Share Holding1.51 %0.13%positive

Promoter Share Holding increased by 0.13% in the most recent quarter to 1.51%.

Interest Coverage Ratio-5.81-negative

Interest Coverage Ratio is -5.81, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding113.31 %0.36%positive

Institutional Holding increased by 0.36% in the last quarter to 113.31.

VIEW LESS


Loading data..

Cytokinetics Inc - Company Profile

What does Cytokinetics Inc do?

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics Inc Management structure

All Gross Remunerations are in USD
Mr. Robert I. Blum
Director, President and Chief Executive Officer
14.37 M
2024
Gross Remuneration
Year
Mr. Sung H. Lee
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
6 M
2024
Gross Remuneration
Year
Mr. Brett A. Pletcher
Executive Vice President and Chief Legal Officer
5.42 M
2024
Gross Remuneration
Year
Dr. Fady Ibraham Malik, M.D.,PhD
Executive Vice President, Research and Development
5.37 M
2024
Gross Remuneration
Year
Mr. Andrew M. Callos
Executive Vice President and Chief Commercial Officer
4.39 M
2024
Gross Remuneration
Year
Mr. Ching W. Jaw
Senior Vice President and Chief Financial Officer
1.68 M
2024
Gross Remuneration
Year

Cytokinetics Inc Board of directors

All Gross Remunerations are in USD
Mr. Robert E. Landry
Independent Director
-
2025
Gross Remuneration
Year

Cytokinetics Inc FAQ

How is Cytokinetics Inc today?
Cytokinetics Inc today is trading in the red, and is down by 0.00% at 39.48.
Cytokinetics Inc is currently trading down 0.00% on an intraday basis. In the past week the stock rose 2.15%. stock has been down -13.69% in the past quarter and fell -41.55% in the past year. You can view this in the overview section.